FDA approves noninvasive Optune Pax device for advanced pancreatic cancer
Short excerpt below. Click through to read at the original source.
The U.S. Food and Drug Administration has approved a first-of-its-kind, noninvasive device, the Optune Pax, for the treatment of adult patients with locally advanced pancreatic cancer. Approval of Optune Pax was granted to Novocure.